A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

CJC-1295 DAC, a synthetic peptide analog of growth hormone-releasing hormone (GHRH), has been a subject of considerable ...

Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 analog with unique ...

Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...

89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets ...

Invivyd reports clinical efficacy data from CANOPY phase 3 trial of pemivibart: Waltham, Massachusetts Friday, November 15, 2024, 18:00 Hrs [IST] Invivyd, Inc, a biopharmaceutical ...

MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life. Following this positive clinical ... peptides and developed through twenty years of empirical ...

especially because alendronate is incorporated in bone matrix and has a biological half-life of more than 10 years. In this study, a total of 1099 postmenopausal women (mean age, 73 ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...